MolecuLight Inc.
11
1
1
4
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
0.0%
0 terminated/withdrawn out of 11 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
50%
2 of 4 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (11)
MolecuLightDX Measurement Feature Clinical Validation
Role: lead
Biofilm Correlation and Validation
Role: lead
Point-spectroscopy Trial
Role: lead
Comparing Wound Area Reduction of Non-healing DFUs Using MolecuLight i:X Versus Standard of Care
Role: lead
Positive Predictive Value (PPV) of Pseudomonas Aeruginosa
Role: lead
Presence of Fluorescence Signature to Predict Graft Failure Using MolecuLight i:X
Role: lead
Evaluation of MolecuLight i:X as an Adjunctive Fluorescence Imaging Tool to Clinical Signs and Symptoms for the Identification of Bacteria-containing Wounds
Role: lead
A Prospective Evaluation of Clinical Equivalence Between iX and PID
Role: lead
Positive Predictive Value of the MolecuLight i:X Imaging Device to Predict the Presence of Bacteria in Chronic Wounds
Role: lead
Post Market Clinical Followup of MolecuLight i:X's PPV to Predict Presence of Bacteria in Wounds
Role: lead
A Prospective, Pilot Evaluation of Device Equivalence
Role: lead
All 11 trials loaded